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Abstract A key aspect of TB pathogenesis that maintains
Mycobacterium tuberculosis in the human population is
the ability to cause necrosis in pulmonary lesions. As
co-evolution shaped M. tuberculosis (M.tb) and human
responses, the complete TB disease profile and lesion
manifestation are not fully reproduced by any animal
model. However, animal models are absolutely critical to
understand how infection with virulent M.tb generates
outcomes necessary for the pathogen transmission and
evolutionary success. In humans, a wide spectrum of TB
outcomes has been recognized based on clinical and epi-
demiological data. In mice, there is clear genetic basis for
susceptibility. Although the spectra of human and mouse
TB do not completely overlap, comparison of human TB
with mouse lesions across genetically diverse strains firm-
ly establishes points of convergence. By embracing the
genetic heterogeneity of the mouse population, we gain
tremendous advantage in the quest for suitable in vivo
models. Below, we review genetically defined mouse
models that recapitulate a key element of M.tb pathogen-
esis—induction of necrotic TB lesions in the lungs—and
discuss how these models may reflect TB stratification
and pathogenesis in humans. The approach ensures that
roles that mouse models play in basic and translational TB
research will continue to increase allowing researchers to
address fundamental questions of TB pathogenesis and
bacterial physiology in vivo using this well-defined, re-
producible, and cost-efficient system. Combination of the
new generation mouse models with advanced imaging
technologies will also allow rapid and inexpensive assess-
ment of experimental vaccines and therapies prior to test-
ing in larger animals and clinical trials.
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Pulmonary necrosis in M.tb life cycle
A long history of human co-evolution with Mycobacterium
tuberculosis (M.tb) suggests that unique immune mecha-
nisms have evolved explaining substantial resistance of
modern humans to the disease [1–3]. However, our species
also proved to be an ideal host for M.tb, such that the bac-
teria lost the need for any other environmental niche and
relied entirely on modifying human body for every stage
of its life cycle. It is generally accepted that to establish
new infection, M.tb reaches terminal airways in small aero-
sol particles generated during cough. Those aerosols are
generated from lung cavities where M.tb accumulates in
large quantities, perhaps in biofilms, at the air interface,
effectively sequestered from host immunity. Thus, from the
evolutionary standpoint, M.tb is an obligate lung pathogen,
such that substantial M.tb-induced destruction of lung tissue
is absolutely required for direct transmission to other
humans. Although the bacteria are capable of achieving this
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goal only in a relatively small fraction of the infected hosts,
this is sufficient for stable colonization of its unique natural
habitat, Homo sapiens. Therefore, understanding mecha-
nisms of host susceptibility enabling M.tb, transmission is
necessary to counter its evolutionary-refined virulence strat-
egy most effectively.
Although animal models have been a lynchpin for
mechanistic studies of TB since Robert Koch’s discovery
of the pathogen, little progress has been made in under-
standing mechanisms of pulmonary destruction caused by
M.tb. Recent experimental work has demonstrated that
despite the uniqueness of human species as a host to
M.tb, mice could be reliably used to study mechanisms
of necrotization in TB granulomas and formation of lung
cavities. Thus, the powerful arsenal of mouse genetic
methods can be utilized to mechanistically dissect those
crucial transitions during the natural course of TB infec-
tion. Below, we review genetically defined mouse models
that recapitulate necrotic TB lesions in the lungs and dis-
cuss how these models may reflect TB pathogenesis in
humans.
Necrosis occurs at various stages of TB infection
There are at least two distinct stages of M.tb infection at
which necrosis can occur: (1) at the initial stage of lung
colonization, which leads to necrosis of individual or
small clusters of macrophages in a primary granuloma,
and (2) during advanced disease where large areas of the
lung are effaced by coalescing granulomas and tubercu-
lous pneumonia. Thus, necrosis delimits the life cycle of
M.tb within an individual and plays an important role in
both establishing persistent infection initially as well as in
the final exit and transmission to a new host. There are
many important mechanistic differences between the two
stages.
The initial contact of M.tb with the host occurs in high-
ly aerated environment, presumably with alveolar macro-
phages in a context of normal lung tissue. The alveolar
macrophages are permissive to M.tb, which establishes its
first replicative niche in this cell. Subsequent interactions
with lung epithelium and possibly innate T cells lead to
recruitment of inflammatory cells from circulation and
establishing clusters of myeloid cells that contain the bac-
teria. These early dynamics cannot be addressed directly
in natural lung environment in humans, but the zebrafish
model of infection with Mycobacterium marinum pro-
vides a detailed view of cellular recruitment and interac-
tions that establish nascent microgranulomas [4–6] before
antigen-specific immunity develops. Although zebrafish
do not have lungs, this model allows detailed cell traffick-
ing studies in vivo and elegantly shows that macrophage
death spreads bacilli to adjacent recruited macrophages
within the same granuloma. Furthermore, when the re-
cruitment of myeloid cells fails to contain M.tb, the bacilli
replicate extracellularly with conspicuous formation of
cords [7]. Multiple host responses contribute to macro-
phage necrosis, including alterations in lipid mediators
and increased TNFα production or deficient recruitment
of new myeloid cells to the site of infection [8]. Similarly,
in the lungs of M.tb-infected C3HeB/FeJ mice (abbreviat-
ed HeB), early micronecrotic lesions form 2–3 weeks
post-infection, when spread of M.tb to adjacent inflamma-
tory cells, as well as robust extracellular replication are
observed [9]. In both the zebrafish model and HeB mice,
the microgranulomas undergoing necrosis are composed
primarily of myeloid cells (macrophages and some
granulocytes). In contrast, different host-pathogen dynam-
ics are observed in the relatively resistant mouse strain
C57BL/6 (B6), where lesions are non-necrotic, contain
few neutrophils, and bacilli remain intracellular.
The early granulomas are composed primarily of mye-
loid cells that initially act autonomously to restrict the
bacterial growth and spread. However, adaptive T cell-
mediated immunity is necessary to contain further pro-
gression and necrotization of granulomas. The bacterial
spread is unstoppable in T cell -deficient mice, where
mycobacteria replicate in unrestricted manner and destroy
the infected tissue. Large areas of necrotic inflammation,
massive bacterial loads, and extensive neutrophil infiltra-
tion are typical for this type of progression, which, how-
ever, lacks the characteristics of organized granulomas.
Thus, the early TB granulomas can follow necrotic and
non-necrotic trajectories depending on the myeloid cell
intrinsic capacity and help of M.tb-induced T lympho-
cytes producing IFNγ (Th1-type response). In both cases,
however, they serve to constrain M.tb and prevent dissem-
ination. In the case of more efficient immune response in
resistant hosts, primary granulomas may be sterilized over
time and undergo calcification. In permissive but
immune-competent hosts, however, small necrotic granu-
lomas establish a nidus of persistent infection, which can
later reactivate and cause post-primary TB.
The exit and transmission strategy of M.tb at the end of
its life cycle is entirely dependent on granuloma spread
and necrosis leading to formation of lung cavities. Those
necrotic lesions become M.tb sanctuaries sequestering the
pathogen from the host immune system and allowing its
replication and transmission via aerosols. This transition
occurs in immune-competent hosts that successfully con-
trolled the primary infection. Thus, the local mechanisms
and the dynamics of necrosis at the advanced disease
stage are not the same as in primary lesions and the
organ- and organism-scale factors may play bigger or dif-
ferent roles. Two different models of necrosis in advanced
TB have been proposed:
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Model
1
This is the gradual necrotization and local expansion
of organized granulomas, including formation and
coalescense of satellite granulomas. Accumulation
of dead macrophages that fail to survive intracellular




This is the rapid dissemination ofM.tb from chronic
lesion causing tuberculous pneumonia, where
necrosis formation may be associated with
thrombosed blood vessels and infarcted regions of
the lungs [10, 11]. Subsequently, M.tb bacilli, dead
inflammatory cells, and dead lung tissue may be
sequestered in a fibrous capsule to re-contain the
pathogen.
Clearly mechanisms and consequences of lung necrosis
need to be considered within the genetic and immunological
context of the host and the stage of disease.We alsowould like
to emphasize the distinction between systemic, lung, and cel-
lular levels that contribute to necrosis and will discuss hypoth-
eses related to necrosis in that order.
Systemic host factors that contribute to necrosis
Arnold Rich pointed out that Btubercule bacilli have very little
power of producing necrosis of tissue in the normal (non-
hypersensitive) body… Injected locally in large amount it
does not kill tissue… A fraction of the number of bacilli,
which could be injected into the tissues without causing ne-
crosis in the normal body, produces violent inflammation and
extensive necrosis in the hypersensitive one^([12], p. 350).
The dual role of inflammation was further investigated by
Arthur Dannenberg, who distinguished cytotoxic delayed-
type hypersensitivity and macrophage-activating cell-mediat-
ed immunity and pointed to a therapeutic potential of manip-
ulating their balance. He used the rabbit model to experimen-
tally reproduce those types [13] and demonstrated that both
types of responses were driven by systemic immunity.
However, at that stage, it was impossible to identify molecular
determinants of Bprotective^ versus Bpathogenic^ inflamma-
tion as specific therapeutic targets. Those classical experi-
ments demonstrating transition from mild protective to
Bviolent^ destructive inflammation implicated systemic host
immune response to M.tb in evolution of the host protective
granulomas into pathogen-favoring ones. However, specific
mechanisms of adaptive immunity causing necrosis in TB
granulomas still remain hypothetical [14].
Local granuloma factors that contribute to necrosis
Mechanistically, the formation of necrotic TB lesions and
liquefaction of cellular debris were attributed to release of
hydrolytic enzymes by macrophages and neutrophils.
Among them are MMP1 and MMP8 [15–18] and serine
proteases [19], which degrade extracellular matrix pro-
teins and basement membranes, participating in lung tis-
sue destruction and stimulating fibrosis. Although those
enzymes may be attractive therapeutic targets, they are
likely to be executors but not the root causes of lung
tissue necrosis.
Recent studies demonstrate that dysbalance of inflammato-
ry pathways may lead to necrotizing inflammation. For exam-
ple, activation of type I interferon (IFN-I) pathway by
instilling tlr3 ligand poly(I:C) in the lungs promoted the de-
velopment of acute necrotic TB lesions via excessive recruit-
ment of myeloid cells [20]. In another model, overexpression
of IL-13 using T cell-specific promoter generated conditions
for the development of well-organized necrotic lung granulo-
mas [21]. Interestingly, the IL-13 overexpression did not re-
duce Th1 responses, which would explain the necrotization by
suppression of the essential host resistance pathway.
Alternatively, increased sensitivity of alternatively activated
macrophages to cytotoxic activity of TNFα in granulomas
may be involved, as hypothesized previously by Rook and
coauthors [22]. Another model of necrotic TB lesions has
been generated using temporal inactivation of essential mech-
anisms of resistance, such as administration of NO inhibitor
and neutralization of IFNγ using injections of monoclonal
antibodies in mice infected with M.tb intradermally [19].
An important concept emerged recently based on stud-
ies of heterogeneous TB granulomas in non-human pri-
mates (NHP) using combination of live imaging, analysis
of RNA expression patterns, M.tb loads, histopathology,
and computational modeling [23–25]. The iNOS and
arginase-1 protein expression in granulomas in situ were
used as surrogate markers for the M1 and M2 macrophage
phenotypes, respectively. The M1/M2 balance emerged as
a best correlate of the granuloma outcome. Double-
positive cells were found in granuloma walls, and pheno-
typically M1 cells increased towards the necrotic center.
In this study, the higher M2 activation did not correlate
with suppression of Th1 responses, as well. In a mouse
model, the expression of arginase-1 was shown to be
modestly protective in granulomas in the absence of
iNOS, and simultaneous Arg1 and iNOS inactivation re-
sulted in exuberant necrotic inflammation [26]. Both of
those observations are more consistent with a possibility
that the arginase-1 pathway does not suppress the NO-
mediated effector pathway, but Arg1 is activated as a
backup effector mechanism, when the more efficient
NO-mediated effector pathway fails to control the bacte-
ria, for example due to hypoxia in large progressive le-
sions. Taken together, the NHP provided a unique data set
unattainable in the mouse model, meanwhile the mouse
model provided a novel mechanist ic insight for
interpreting the NHP data.
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Factors that contribute to macrophage necrosis
At a cellular level, mechanisms of macrophage death directly
caused byM.tb are under intense investigation. Roughly, they
can be divided into two categories: (1) active mechanisms,
whereby virulent mycobacteria or host produce toxic molec-
ular mediators that cause macrophage death, and (2) passive
mechanisms, where bacillary replication in macrophages re-
sults in lysis, essentially a Bload-driven^ death. The former
category focuses on specific pathways that determine macro-
phage death modality. For example, the balance of lipid me-
diators PgE2 and lipoxin A4 has been shown to control mem-
brane repair of the infected macrophages and apoptotic vs
necrotic cell death [27, 28], as well as production of TNFα
[29], whereas the higher concentrations of TNFα induced
necroptotic pathway in macrophages [30]. The necrotic mac-
rophage death is perceived as more detrimental for the host
that might be associated with necrotic granuloma formation
in vivo, while apoptotic death has been associated with host
resistance and bacterial control [27, 31, 32].
M.tb produces multiple products that induce macrophage
necrosis in vitro. Cord factor (trehalose 6,6′-dimycolate or
TDM) is a mycolic acid-rich membrane glycolipid identified
decades ago and is a well-known virulence and immunomod-
ulatory factor ofM.tb. TDM is particularly interesting because
it may induce rapid macrophage necrosis. Early secreted anti-
genic target-6 (ESAT-6) is a virulence factor encoded within
the RD1 region [33], which is absent from the vaccine strain
Mycobacterium bovis BCG. ESAT-6 triggers necrosis directly
[34] or indirectly by phagosomal rupture allowingM.tb access
to the cytoplasm [35, 36] and activation of NLRP3
inflammasome [37]. Another cytotoxin CpnT has been recently
discovered that kills macrophages via hydrolysing macrophage
NAD [38, 39]. However, those toxic factors are not sufficient to
induce necrotic granulomas in the genetically resistant mice.
Meanwhile, even avirulent (ESAT-6 negative) M. bovis BCG
was capable of inducing granuloma necrosis in immunodefi-
cient Mendelian susceptibility to mycobacterial diseases
(MSMD) human patients or T cell-deficient mice. The later
facts are consistent with a burst size hypothesis, where unre-
stricted growth of intracellular mycobacteria results in achiev-
ing maximal load and eventually death of the infected cell [40].
A hybrid hypothesis stipulates that membrane-toxic mycobac-
terial products produced intracellularly may allow M.tb escape
from vacuole to cytoplasm, where it can either replicate more
rapidly to achieve the burst size or actively induce macrophage
cell death via activation of type I IFN pathway [41, 42].
This brief review of literature suggests the co-existence,
and potential cooperation, of multiple pathways leading to
necrosis of granulomas. Here, we would like to emphasize
that causality of necrosis may significantly differ between an-
imal hosts and experimental systems, as well as between hu-
man patients.
Genetic variation in mice controls necrotizing
responses to M.tb
Many animal models are used to studyM.tb lesions including
mice, guinea pigs, rabbits, non-human primates, bovine
calves, zebrafish, rats, ferrets, mini pigs, fruit flies, nematodes,
planarians, and even amoebas [43–56]. Due to the small size,
cost-efficiency, and availability of reagents, mice are widely
used and have been crucial for determining immunological
requirements that restrict M.tb growth [57, 58]. However,
the two most commonly used inbred laboratory mouse strains
(C57BL/6 and BALB/c) do not develop necrotizing lesions
[56, 59, 60] which, unfortunately, have led to general criticism
of the mouse model. When considering responses at the
mouse population level, however, it becomes apparent that
necrotizing responses to M.tb commonly occur in inbred
(C3HeB/FeJ, DBA/2, CBA/J, I/St), inbred crossed (HET3),
and even outbred crossed (Diversity Outbred) mice [61–67].
The spectrum of necrosis includes apoptosis and necrosis of
individual macrophages, necrotizing granulomas with fibrotic
capsule, tuberculous pneumonia with intra-alveolar neutro-
philic exudates, and fibrin thrombosis of lung alveolar capil-
laries (Fig. 1a–d). Similar necrotizing responses are associated
with and appear to precede cavity formation in humans and
larger animal models (rabbits and NHPs) [68–70]. Although
cavities were not reported in mice in the past, their formation
has been well documented recently in C3HeB/FeJ [71, 72]
and CBA/J mice (Fig. 1e–f) following their typical necrotizing
responses.
Granulomas are often described with stereotypical orga-
nization: focal aggregates of central myeloid cells with pe-
ripheral lymphocytes and a fibrous capsule that separates the
immune cells from the adjacent normal tissue. This is a
simple model to envision; however, in reality, a significant
heterogeneity between granulomas is observed even within
the same individual in the clinic and in experimental animal
models. Necrotic granulomas may develop necrotic centers
(necrotizing granulomas) or be infiltrated by neutrophils
(suppurative granulomas), although the conditions which
drive those transitions are not fully known. Recent studies
in C3HeB/FeJ mice link necrotizing structural and cellular
responses to M.tb with morbidity [72, 73]. Type I, II, and III
granulomas were characterized, but the lesions are not quite
stereotypical granulomas mentioned above. Regardless of
terminology, highest morbidity was observed in type II le-
sions, which were dominated by necrotizing responses:
unencapsulated tuberculous pneumonia with macrophages,
neutrophils, necrotic cell debris packed within alveolar
spaces, and abundant intra- and extracellular bacilli. Type I
lesions were smaller necrotizing lesions with central necrosis
surrounded by macrophages, neutrophils, and peripheral fi-
brosis with abundant extracellular bacilli in the necrotic cen-
ter and intracellular bacilli in foamy macrophages at the
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periphery. Type III were non-necrotic lesions composed of
mononuclear cells and macrophages in alveoli, perivascular
and peribronchiolar lymphocytic aggregates, and alveolar
septal interstitial fibrosis. M.tb bacilli were intracellular with-
in macrophages and relatively scarce. These lesion types are
not unique to C3HeB/FeJ mice. We observed lesions iden-
tical to type I and type III in chronically infected CBA/J
mice but not type II [64]. We also recently reported a similar
spectrum in M.tb-infected Diversity Outbred mice. Highest
morbidity occurred in the individuals that developed necro-
tizing neutrophilic tuberculous pneumonia (i.e., type II le-
sions) and these same mice had the highest bacillary burden
[66]. We additionally observed capillary thrombosis in type
II lesions [66] with loss of differential staining suggestive of
infarction and coagulation necrosis. It is likely that geneti-
cally diverse humans and mice share underlying mecha-
nisms for these complex necrotizing responses, because
humans with post-primary TB similarly develop thrombosis,
coagulation necrosis, and lung infarction without organized
granulomas [10, 11, 74]. Thus, the genetically diverse
mouse models morphologically recapitulate all major forms
of pulmonary TB in other species in a reproducible geneti-
cally controlled manner.
Mechanisms of necrotizing responses as studied
in mouse models
Neutrophils as mediators of necrotizing responses toM.tb
Neutrophils are suicide bombers of the innate immunity with the
primary function of killing extracellular pathogens. In this pro-
cess of eliminating pathogens, neutrophils deploy numerous po-
tentially host-damaging molecules such as matrix
metalloproteases from cytoplasmic granules; abundant and po-
tent oxidants; and the neutrophils themselves undergo necrosis
releasing formyl peptides, complement C5a, and other mole-
cules, which may stimulate Bnecrotaxis^ (a type of neutrophil
chemotaxis towards sites of cells and tissue death) [75–84].
These molecules from dead and dying bacterial and host cells
are the most potent stimulators of neutrophil recruitment to sites
of infection and cell/tissue death [79, 84]. In TB, large numbers
of neutrophils accumulate in airways of pulmonary TB patients
and in airways of mice that develop necrotizing responses [66,
72, 85–87] where dead neutrophils are packed in alveoli and
terminal bronchioles within and adjacent to necrotizing granulo-
mas [66, 72], presumably in response to macrophage death in-
duced by rapidly replicating, virulent intracellular bacteria [40].
Fig. 1 Manifestation of necrotizing responses and cavitation induced
in vivo in the lungs of mice experimentally infected with
Mycobacterium tuberculosis. Formalin-fixed, paraffin-embedded lung
sections were stained with hematoxylin and eosin (a through d) or
stained with a modification of Ziehl-Neelsen’s acid-fast method (f).
Death can be observed in individual macrophages as apoptosis
recognized by nuclear fragmentation, magnified 1,000 times, encircled
(a). Necrosis of an individual macrophage in an alveolar space is
recognized by cytoplasmic eosinophilia and a pyknotic, condensed
nucleus, magnified 1,000 times (b). Alveolar septae are present but
difficult to recognize due to accumulation of dead inflammatory cells
and cellular debris within alveolar air spaces, magnified 400 times (c).
As the necrotizing process continues, fibrin thrombosis of capillaries is
observed as a transition from a capillary with red blood cells to a capillary
containing eosinophilic fibrillar material consistent with fibrin (arrows),
magnified 400 times (d). Finally, complete destruction of alveolar septae
allows necrotic regions to coalesce and undergo liquefaction and removal
of necrotic material, thus contributing to cavity formation, magnified 20
times normal (e). Cavities contain variable necrotic debris in which
abundant acid-fast bacilli are detected, magnified 400 times (f). (a–d)
necrotic lung lesions in supersusceptible DO mouse; (e–f) cavity in the
lung of a CBA/J mouse
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Neutrophils and their chemokines are markers of pulmo-
nary TB in humans and in mice [40, 64, 66, 72, 73, 85–92].
Some evidence suggests that neutrophils contribute to TB be-
cause administration of antioxidants and anti-inflammatories
(which may dampen neutrophil responses) decreased TB dis-
ease progression [93, 94] and because few neutrophils are
present when bacillary replication is slowed [40]. However,
only a handful of studies definitively link neutrophils [95] or
their chemoattractants (e.g., CXCL5) [96] with increased sus-
ceptibility to M.tb, and others indicate that neutrophils are
cellular biomarkers of failed immunity [92]. There are no
studies that definitively prove that neutrophils drive necrotiz-
ing responses, and no studies have clearly defined genetic
control of neutrophil recruitment. Definite hints exist because
neutrophil responses vary with the hosts’ genetic architecture
in humans and in experimentally infected mice [66, 85, 95,
97], and quantitative trait loci (QTLs) for TB susceptibility
overlap with genes that may control neutrophil responses [91].
There are fundamental knowledge gaps in understanding
how neutrophils contribute to macrophage and granuloma ne-
crosis, but there are a number of candidate mechanisms to be
tested. At the cellular (macrophage) level, neutrophils may
cause lipid peroxidation of cell membranes, resulting in mac-
rophage necrosis and release of bacilli. At the granuloma and
lung tissue level, neutrophil influx could be more even more
detrimental: (1) by causing lipid peroxidation of epithelial and
endothelial cell membranes which irreparably damages lung
tissue; (2) by proteolytic digestion of collagen-rich matrix and
basement membranes of the lung alveolar septae; and (3) by
physically obstructing airways which disrupt normal pulmo-
nary function.We additionally theorize that neutrophils contrib-
ute to lung damage, which precedes cavitation by promoting
thrombosis and infarction. This is supported by the facts that
neutrophil granules contain pro-thrombotic molecules and that
NETs from dying neutrophils also promote thrombosis [68,
98–100]. Additionally, this is supported by in situ observations
of fibrin thrombi within capillaries adjacent to necrotic alveolar
septae (Fig. 1d) as well as thrombosed vessels and necrotic lung
tissue in patients with cavitary TB [11, 74].
Current evidence shows that neutrophil roles are complex.
The abundance of neutrophil involvement in necrotizing re-
sponses and lesion progression does not prove, however, that
neutrophil activity is the mechanistic cause of macrophage
necrosis, granuloma necrosis, or lung tissue necrosis in TB
lesions. At the early stage of infection, neutrophils can be
protective by phagocytizing and killing a fraction of M.tb
bacilli through oxidative mechanisms [101]. At the later
stages, however, the excessive recruitment of neutrophils to
TB lesions in the lung may serve as a common mechanism
downstream of pathological reactions, which are triggered or
maintained by other cell types. As an overall trend, in the
susceptible mouse strains, neutrophils exacerbate susceptibil-
ity [95, 97]. However, it remains to be established whether this
occurs because the susceptible mice have a genetic propensity
for increased neutrophil recruitment to the lungs following
M.tb infection, intrinsic functional defects of neutrophils, or
it occurs downstream of other cells’ genetic defects.
In part, the paucity of known neutrophil-mediated mecha-
nisms reflects scarce methodologies to manipulate and track
neutrophils in vivo. Fortunately, new tools addressing roles
for neutrophils have recently become available. This includes
genetically diverse populations of mice (Diversity Outbred,
Collaborative Cross) [102, 103]; immortalized neutrophil pro-
genitor cells that can be manipulated in vitro and in vivo
[104]; and neutrophil imaging technologies to track neutro-
phils in vivo over time in M.tb-infected mice. Eventually,
those and other novel approaches will allow definitive mech-
anistic analyses of neutrophil contributions to the
necrotization of TB lesions using mouse models, applicable
to other species.
Macrophage roles in necrotizing responses
A scrupulous work by the Kornfeld laboratory provided con-
vincing experimental evidence that macrophage necrosis may
trigger neutrophil recruitment to sites of M.tb infection [40,
105]. Using relatively resistant C57BL/6 mice infected with
M.tb strains of varying virulence, they showed that higher
neutrophil recruitment paralleled higher M.tb virulence and
the rates of intracellular bacterial replication. Macrophage
death in that model was driven by bacterial load (burst size),
achieving which was followed by increase in uninfected and
M.tb-infected neutrophils in the lungs [40]. This indicates that
macrophage necrosis and release of M.tb indeed recruit neu-
trophils which phagocytize the extracellular M.tb bacilli. The
authors also hypothesized that the neutrophil recruitment to
sites of M.tb infection fundamentally reflects necrotaxis and
that accumulations of dead cells and bacterial products may
establish a self-sustaining positive feedback loop of neutrophil
recruitment and death, even in the absence of bacterial repli-
cation. Thus, initially triggered by bacterial replication and
macrophage death, neutrophil recruitment could accelerate le-
sion progression in autonomous manner and create the envi-
ronment favorable for further M.tb replication. However, in
the resistance B6 mice, this hypothetical amplification mech-
anism did not result in the formation of necrotic granulomas.
Additional studies are necessary to determine whether
targeting neutrophil recruitment can prevent or reverse the
formation of necrotizing granulomas in those susceptible
mouse strains, in which necrosis is caused by primary genetic
defects of macrophages.
Genetic studies of necrotizing granulomas
We addressed mechanism(s) of necrotizing granulomas using
an unbiased forward genetic approach—Bfrom phenotype to
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gene.^ To map genetic loci controlling the formation of nec-
rotizing granulomas in the lungs of C3HeB/FeJ (HeB) mice,
we performed classical linkage analysis using crosses with the
C57BL/6 (B6) mice [106, 107]. The B6 inbred strain is the
most widely used inbred mouse strain in TB research, as a
wild-type (wt) control for many genetically engineered (most-
ly knockout) mice of the same background. The wt B6 mice
are permissive to infection with virulent M.tb but efficiently
control M.tb replication due to the development of T cell-
mediated immunity [57, 58]. Following infection, they typi-
cally survive greater than 12 months, and TB disease progres-
sion may reflect age-related changes in immune responses or
immunological exhaustion [56] with up to 80 % of their lung
occupied predominantly by macrophages and lymphocytes
with interstitial fibrosis but lacking necrotizing granulomas.
Using the QTL analysis, we demonstrated a complex poly-
genic pattern of TB control, with both parental strains, B6 and
HeB, carrying resistance and susceptibility alleles [108]. We
focused our attention on four candidate loci (QTLs) at which
the B6 mice carried resistance alleles on chromosomes 1, 7, 15,
and 17. The chr.17 QTL overlapped with the mouse major
histocompatibility complex (MHC) locus (H-2). Consistently,
congenic mice that carried the C57BL/6-derived H-2b allele on
the C3H background developed more prominent Th1 response,
both after M.tb infection and BCG vaccination. However, this
effect was not sufficient to prevent the formation of necrotizing
granulomas [109, 110]. To study the chromosome 1, 7, and 15
loci, we have generated a series of congenic mice by transfer-
ring large fragments of C57BL/6-derived chromosomes on the
HeB background: each congenic strain received a fragment of
one B6 donor chromosome. We found that only the B6-
resistant allele at the chromosome 1 locus was necessary and
sufficient to prevent the formation of necrotic granulomas after
infection with virulentM.tb [61, 111]. The congenic HeB mice
that carried the B6-derived allele at that locus lost their extreme
susceptibility and resembled other standard substrains of C3H
(C3H/HeJ, C3H/HeN, etc.) in terms of their survival and non-
necrotic lung pathology [32, 112]. Therefore, we named the
chromosome 1 locus sst1, for Bsuper-susceptibility to
tuberculosis.^ When the sst1 susceptibility allele was trans-
ferred from HeB to the resistant B6 background, the resultant
congenic mouse strain B6.C3H-sst1S also developed necrotiz-
ing granulomas in the lungs. Together, these results clearly
demonstrated the dominant role of the sst1 locus in controlling
the formation of necrotizing granulomas [61].
Comparing mice that carried the sst1S (susceptible) allele
on two distinct genetic backgrounds, HeB and B6, we ob-
served that the necrotizing granulomas developed only in the
lungs, regardless of the route of M.tb infection—either the
high dose intravenous (i.v.) or a low dose aerosol. The i.v.
infections resulted in more rapid TB progression and death,
as compared to the aerosol model. Nevertheless, there was a
significant difference between the HeB and B6.C3H-sst1S
mice in median survival time (MST), 35 and 86 days, respec-
tively, consistent with the overall higher TB resistance of the
B6 mice due to the presence of resistance alleles at other, not
linked to sst1, loci. However, the overall outcome was similar
in both cases—mice died with large coalescing necrotizing
lung lesions dominated by neutrophilic exudate and high my-
cobacterial loads, with the bacilli occupying intra- and extra-
cellularly compartments [61, 107]. Those lesions closely re-
sembled the type II lesions, according to classification of
Irwin et al. discussed above [73].
A different type of lesion was observed in the lungs after a
low dose aerosol infection (with a retained dose of M.tb 15–
25 CFU at 24 h). Well-organized necrotizing granulomas de-
veloped in the lungs of both sst1S mouse strains, HeB and
B6.C3H-sst1S, 8–12 weeks post-infection. Remarkably, the
development of necrotic lesions followed different trajectories
and resulted in necrotic lesions different in their wall structure,
as well as in the abundance and localization of the bacterial
populations. At 5–6 weeks post-infection, the HeB developed
coalescing tuberculous pneumonia. Abundant acid-fast bacilli
were found within myeloid cells occupying alveolar spaces.
Large necrotic foci could be found within the pneumonic areas
at that stage surrounded by neutrophils that formed demarca-
tion zone around necrotic foci. The appearance of organized
necrotic lesions in the HeB mice followed the pneumonia and
coincided with stabilized bacterial growth. In this model, the
bacteria resided both extracellularly within the necrotic core,
as well as inside macrophages within the granuloma wall,
including the most outer layers and outside of the organized
lesions.
Necrosis of TB lesions in B6.C3H-sst1S followed a different
pattern (Fig. 2). Initially, TB lesions in their lungs developed
with kinetics similar to the B6 mice: after a period of rapid
replication for 2 weeks, the bacterial loads were reduced five-
to tenfold coinciding with activation of the adaptive immunity.
By the sixth week, the bacterial load increased compared to B6
mice but remained 20–50 times lower than in the HeB mice
(Fig. 2b). No alveolar exudates, pneumonia, necrotizing gran-
ulomas, extracellular bacteria, or neutrophil infiltration were
observed at this stage. The lung lesions were compact, primar-
ily composed of mononuclear phagocytes and lymphocytes
(Fig. 2a). The extrapulmonary bacterial loads were low, dem-
onstrating efficient systemic control of the bacterial replication.
However, 9–12 weeks post-infection, large organized granulo-
mas several millimeters in diameter, often occupying almost a
whole lobe in the mouse lung, were formed. Compared to HeB,
their wall was much thicker with more prominent fibrotic cap-
sule adjacent to necrotic core. The characteristic concentric
layers composed of macrophages, fibrosis, and tertiary lym-
phoid tissue formed around caseous center. The lymphoid layer
contained CD4 and CD8-positive cells and CD-19-positive B
cells organized in follicles. Few T cells penetrated the deeper
layers of the lesion, while macrophages were predominant cells
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in contact with the necrotic masses. The bacteria were scarce
compared to HeB and found almost entirely within necrotic
core as single cells, suggestive of slow replication or non-
replicative state. Occasionally, the intracellular bacteria were
found within granuloma wall inside activated (iNOS-positive)
macrophages but not outside the lesions. Obviously, the
B6.C3H-sst1S granulomas contained the bacterial spread more
effectively compared to HeB. Consistent with more efficient
control of M. tb, the B6.C3H-sst1S mice survived significantly
longer than the HeB mice—40 and 20 weeks after a low dose
aerosol infection, respectively.
The above studies demonstrated complex genetic control of
the necrotizing phenotype in the mouse model. First, it revealed
the existence of a major genetic locus sst1 specifically control-
ling the development of necrotizing granulomas per se, rather
than necrosis being an outcome of a cumulative effect of many
loci with equally important, but weaker, individual effects.
Other genetic loci serve as quantitative modifiers: they deter-
mine specific immunological context and stages through which
lesions reach the necrotic phase. Once necrotic foci appear,
however, we observe some morphologic convergence on vari-
ous genetic backgrounds. Perhaps necrotic products provide a
morphogenic trigger for the lesion organization and pathogen
containment via encapsulation. To sum, the genetic analysis of
necrotizing granulomas in the HeB mouse model reveals a
common underlying mechanism that can be genetically and
functionally uncoupled from mechanisms of host resistance
controlling the bacterial loads (Fig. 2c). The sst1-mediated
mechanism is more suitably defined as a mechanism of cell
or tissue resilience to inflammatory damage.
The sst1 locus controls intrinsic macrophage function The
availability of the sst1 congenic mouse strains allowed in-depth
analysis of the cellular basis of the sst1-mediated phenotype.
Using reciprocal bone marrow transplantation and adoptive
transfer experiments, we established that sst1 controlled innate
immunitymediated by the bonemarrow-derived non-lymphoid
cells [9, 32, 113]. We also established that this mechanism
controlled progression of infections caused by several taxo-
nomically unrelated intracellular bacteria (Listeria
monocytogenes [113], Chlamydia pneumoniae [114], and
Francisella tularensis LVS (in preparation). A candidate gene
intracellular pathogen resistance 1 (Ipr1) encoded within sst1
locus and expressed in activated macrophages has been identi-
fied using positional cloning [32]. We reported that mouse
macrophages isolated from Ipr1-deficient mice and infected



































Fig. 2 The sst1 locus controls necrosis of TB granulomas. a TB
granulomas in the lungs of B6.C3H-sst1 mice 6 (left panels) and
12 weeks (right panels) after a low dose aerosol infection with virulent
M.tb Erdman. TB granulomas double stained with hematoxylin and eosin
(upper panels) and auramine-rhodamine (lower panels). The acid fast
fluorescent staining with auramine-rhodamine identifies intracellular (at
6 weeks) and extracellular (at 12 weeks) M.tb. Caseous necrotic center
containing M.tb is surrounded by organized wall at 12 weeks. b Total
M.tb loads in the lungs of the parental C3HeB/FeJ (C3H) and C57BL/6J
(B6) and the sst1-congenic (B6-sst1S) mouse strains. c Effects of the sst1
locus and the host genetic background on lung tissue damage and M.tb
lung burdens: the sst1-mediated control of granuloma necrosis (Y-axis) is
uncoupled from the bacterial (X-axis)
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with intracellular pathogenic bacteria in vitro die more readily
via non-apoptotic, presumably necrotic, death. Recent work on
characterization of the sst1/Ipr1-mediated pathway in macro-
phages is beyond the scope of this review and will be published
elsewhere (Bhattacharya et al., in preparation). Suffice it to say
that Ipr1 is a nuclear protein induced in activated macrophages
and involved in control of macrophage stress responses. Its loss
of function makes the sst1 susceptible macrophages, HeB and
B6.C3H-sst1S, more sensitive to stress and prone to death upon
infection with intracellular bacteria.
This mechanistic insight provides an explanation for in-
complete protection offered byBCGvaccination in HeBmice.
On the one hand, the BCG vaccine induces protective ac-
quired immune response in HeB mice that reduces M.tb
growth and extends their survival [9, 110, 115, 116].
Obviously, earlier activation of mycobacteria-specific Th1 re-
sponse in BCG vaccinated animals produces a significant
modifier effect on the sst1S phenotype. However, it does not
remedy the mechanistic root cause of necrosis in macrophages
and the necrotic lesions still develop, albeit with significant
delay in time [9]. Therefore, the sst1 deficiency of macro-
phages poses a limit to BCG vaccination efficiency. Because
current vaccine candidates againstM.tb aim at activating mac-
rophages via T cell-mediated help, even highly immunogenic
vaccines may fail in immune competent hosts whose TB sus-
ceptibility is based on certain macrophage defects.
Together, our findings on a specific role of the sst1 pathway
in macrophages extend the burst size hypothesis of Kornfeld
et al., which has been established in B6 mice. We suggest that
the burst size being intrinsic to macrophages is not a fixed
property but may vary depending on host genetic background
and environment, which determine macrophage resilience.
Meanwhile, the effector mechanisms of resistance control
the rates of intracellular bacterial survival and replication,
i.e., determine whether and how fast a certain burst size is
achieved. Therefore, interactions of resistance and resilience
mechanisms would produce cumulative effects that determine
the lesion dynamics and types of immunopathology. We an-
ticipate that this framework is broadly applicable to the anal-
ysis of the complex genetic control of host interactions with
M.tb and other intracellular pathogens [117].
Awork on dissecting the genetic control is ongoing in other
mouse models of necrotic TB inflammation. Using a cross of
I/St and B6 mice, Apt and colleagues have mapped three
QTLs on chromosomes 3, 9, and 17 [118–120]. The chromo-
some 17 QTL has been narrowed down to a smaller candidate
region encompassing mouse MHC using a series of interval-
specific congenic mice. Functional analysis demonstrated that
the susceptible I/St-derived MHC allele was associated with
higher bacterial loads, more pronounced inflammation, and
lower Th1 cell response in the lungs after aerosol infection
with virulentM.tb [121–123]. In yet another model of necrotic
TB inflammation in DBA/2 mice, two QTLs have been
mapped to chromosomes 8 and 19 also in a cross with
C57BL/6. Of those, the chromosome 19 QTL (named trl4)
specifically controlled the bacterial replication in the lungs
after aerosol infection with M.tb [124, 125]. It remains to be
established in those models whether lung necrosis is
epistatically controlled by a major locus in a manner similar
to sst1, or the necrotic phenotype is due to additive effects of
several susceptibility loci controlling the bacterial replication.
A more comprehensive dissection of pathways to necrotiz-
ing granulomas may be achieved using genetically heteroge-
neous populations, such as Diversity Outbred mice, which are
as diverse as the human population. A substantial benefit of
this particular mousemodel is that Diversity Outbred genomes
are suited for high-resolution genetic mapping and have al-
ready identified novel genetic associations with a variety of
traits [102, 103, 126–129], providing proof of concept the
same will be true for TB research. The genetic heterogeneity
comes from eight distinctive founder strains of which five are
inbred laboratory strains and three are wild-derived strains
[102, 129]. Only three (C57BL/6, 129, and A/J) have been
used in M.tb research, identifying the importance of Th1-
mediated resistance and providing some insight into suscepti-
bility [56, 130–132]. Responses of the other five founder
strains (NOD/LtJ, NZO/HlLtJ, CAST/EiJ, PWK/PhJ, and
WSB/EiJ) have not yet been published.
DO mice have been used in only three M.tb studies one of
which included vaccination responses only, not infection [65,
66, 85]. Following aerosol infection, approximately half of DO
mice developed necrotizing lung granulomas with neutrophilic
tuberculosis pneumonia which resembled type II lesions de-
scribed in [73] (Fig. 1a–d). All parental mouse strains are im-
mune competent. The fact that excessive neutrophil recruitment
and abundant neutrophil chemokines were common TB disease
correlates in Diversity Outbred mice [66] suggests that necro-
tizing granulomas and neutrophilic tuberculosis pneumonia
may be triggered by multiple genetic loci whose interactions
control lung damage caused by TB infection. Some of those
loci may work upstream of neutrophil recruitment controlling
macrophage death. In this situation, neutrophils may serve as
bystanders but it is, more likely, that neutrophils amplify tissue
damage initiated by other causes. Meanwhile, other genetic loci
may increase cell-autonomous neutrophil activity [133, 134].
Both possibilities would be consistent with the ameliorating
effect by neutrophil blockade, as demonstrated in several stud-
ies where positive effects of neutrophil depletion were detected
but only in strains already prone to developing necrotizing
granulomas and not in resistant B6 mice [94, 95, 97, 135].
We anticipate that high-resolution genetic mapping follow-
ed by identifying stages of the disease progression, cell types,
and functions controlled by individual genetic loci in diverse
mouse models may reveal distinct pathways for necrotizing
granuloma formation and progression, as well as mechanistic
points of their convergence.
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TB spectrum: of mice and men
The fundamental difference between the human and mouse
species as hosts for M.tb is that modern human populations
are a product of long co-evolution with M.tb, while mice are
not. In human populations exposed to M.tb, the highly sus-
ceptible individuals are selected against and genetic variants
that confer high degree of susceptibility to TB remain at low
frequency. Also, there is a significant proportion of innately
resistant individuals that remain infection-free even in high
exposure settings, ranging between 20 and 70 % in different
studies. Mice are not naturally infected with M.tb, do not
transmit the bacteria via aerosols, and were not subjected to
natural selection by this pathogen. Not surprisingly, the hu-
man and mouse TB spectra do not fully overlap. As currently
known, the spectrum of natural genetic variation in TB sus-
ceptibility among laboratory mice is shifted towards suscepti-
bility as compared to modern human populations. Below, we
propose operational stratification of humans in terms of TB
susceptibility and identify matching genetically defined
mouse strains (Table 1).
In the order of decreasing resistance, humans can be clas-
sified as innately resistant (IR), permissive resistant (PR), per-
missive susceptible (PS), and extremely susceptible (ES).
The IR individuals remain infection free after repeated ex-
posure to M.tb. presumably due to effector mechanisms of
innate immunity that effectively eliminate M.tb before it es-
tablishes the primary infection site in the lung. Those mecha-
nisms might be evolutionary acquired and refined only in
humans. Macrophage-mediated killing of mycobacteria via
vitamin D-stimulated production of bactericidal peptides is
one of them. Perhaps other mechanisms also exist, but their
discovery is complicated, exactly because of a lack of appro-
priate animal models. To date, no IR equivalent has been
identified among standard laboratory mouse strains. Upon ex-
perimental infection, each mouse strain is permissive to some
degree and remains either chronically infected (PR equivalent)
or develop primary progressive TB (PS equivalent). The ge-
netic analysis of human cohorts that remain infection free in
high exposure settings, including HIV-infected patients, is
perhaps the best approach to discovering human-specific IR
effector mechanisms. Subsequently, mouse models can be ge-
netically engineered to reproduce those mechanisms using
various methods to Bhumanize^ mouse genes.
The ES individuals represent another phenotypic extreme
in humans—monogenically controlled severe mycobacterial
diseases (MSMD). Inactivating mutations in essential path-
ways of antituberculosis immunity in MSMD patients results
in susceptibility to normally apathogenic environmental
mycobacteria and avirulent vaccine strain of M. bovis BCG
[136, 137]. In those individuals, disseminated mycobacterial
diseases develop due to unrestricted replication of
mycobacteria, and necrosis within lesions is driven by high
bacterial loads. Albeit rare, those conditions represent a sig-
nificant therapeutic challenge. In this category, the mouse and
human studies demonstrated remarkable complementarity.
First, the devastating effects of inactivating mutations in genes
of IL12-IFNγ axis and IRF8 on resistance to M.tb were de-
scribed in mice [138–140]. These experimental findings cor-
rectly predicted extreme susceptibility to mycobacteria among
the human mutation carriers. Each mutation inactivating the
essential pathway of host resistant to M.tb produces strong
independent effect irrespective of genetic modifiers,
explaining the monogenic, Mendelian, pattern of inheritance.
The discovery of novel MSMD genes using exome re-
sequencing in affected humans [141] can be mechanistically
followed-up using genetically engineered mice with various
types of mutations introduced in a corresponding gene. The
mutants, either natural or genetically engineered, would serve
as accurate models of MSMDs for both mechanistic studies
and therapeutic applications.
The majority of human tuberculosis spectrum rests be-
tween the above extremes and is represented by groups of
people who are permissive for tuberculosis infection but less
susceptible than the ES group. Those individuals can be fur-
ther subdivided into PR and PS subpopulations. The PR pop-
ulation allows implantation of M.tb and establishing chronic
asymptomatic infection, while the PS population allows pro-
gression of the infection towards overt disease within months
of the initial exposure.
Most of the mouse strains that develop necrotic lung le-
sions match the PS category within the human spectrum.
Thus far, the mouse model of necrotic TB lesions in C3HeB/
FeJ (HeB) has been evaluated and successfully adopted by
several research groups. Pathomorphological diversity of TB
lesions in HeB mice and their similarity to necrotic lesions in
other animal models and humans enabled modeling physio-
logically relevant states of the bacteria and allowed the anal-
ysis of drug distribution within necrotic lesions [62, 72, 73,
142–144]. Other mouse strains that develop necrotic TB le-
sions, such as CBA, I/St, A/J, and DBA/2, may be used to
expand the lesion diversity, which is desirable for preclinical
testing of antibacterial drugs.
From the mechanistic standpoint, perhaps no single inbred
mouse strain is sufficient to reproduce the heterogeneity of
pathways leading to the necrotic phenotypes. All of the above
mouse strains possess essential mechanisms of host resistance
to TB, but the genetic basis underlying their susceptibility
most likely differ between the strains. As discussed above,
those mouse phenotypes represent complex genetic traits,
where allele combinations shape the phenotypes by producing
quantitative and threshold effects. Their discovery via system-
atic forward genetic analysis should reveal genes and path-
ways that play important roles in controlling progression to-
ward necrotic TB lesions in mice. Corresponding mutations
may not be sufficiently represented in modern human
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populations, because of their elimination via negative selec-
tion by TB. Due to their low frequency, they may remain
undetectable in human genome-wide association studies
(GWAS). Nevertheless, those pathways may be compromised
in humans, as well, due to environmental factors, such as co-
infections, co-morbidities, and stress among others.
Therefore, mechanisms of susceptibility discovered in mice
may serve as valid targets for host-directed therapies (HDTs)
in humans, while a corresponding mutant mouse strain would
serve as a genetically defined model for preclinical evaluation
of HDTs targeting a specific pathway.
The PR, human hosts control the pathogen, survive through
reproductive age, and are not subjected to intense negative
selection [145]. The PR individuals do not readily eradicate
M.tb; however, their immunity is adequate for the disease
prevention and remains so during lifetime in the majority of
LTBI cases. We believe that this group produces the biggest
epidemiological impact for two reasons: first, it represents a
large reservoir of latent M.tb infection (LTBI) and, second,
yields individuals that may efficiently transmit the bacteria
via aerosols upon the LTBI reactivation. Therefore, dissecting
mechanisms of TB control in this group using animal models
is especially important.
Perhaps, the best-studied mouse model resembling PR
humans is represented by the commonly used C57BL/6 (B6)
mice. These mice control infection withM.tb delivered either
by aerosol or i.v. routes. After a low dose aerosol infection, a
period of rapid M.tb replication lasts for approximately
2 weeks during whichM.tb doubling time roughly approaches
the doubling time in liquid culture, i.e., the bacterial growth
proceeds in unrestrictedmanner. After reaching the peak in the
lungs, the bacterial load is reduced five- to tenfold commen-
surate with the onset of T cell response in regional lymph
nodes and migration of M.tb-specific T cells into the lung
lesions. Those stable levels are maintained for several months
to a year, and no necrotic granulomas have been observed in
un-manipulated animals, indicating that pathways that restrict
necrosis in TB lesions remain intact. C57BL/6 mice eventu-
ally die as the lungs become filled with degenerating macro-
phages and lymphocytes and development of concurrent sep-
tal fibrosis. The same type of lesions in humans could corre-
spond to latent infection. The BCG vaccination of B6 mice
prior to infection further reduces the bacterial loads, but nei-
ther prevents the infection nor results in M.tb eradication.
Pathways responsible for necrosis in TB granulomas can be
identified using genetic analysis in crosses of mice
representing the PR-like (B6) and the PS-like (I/St, CBA,
A/J, and DBA/2) mouse strains as well as the DO and
Collaborative Cross mice. Genetic mutations identified in
the PS-like mice would point towards pathways, whose inac-
tivation result in granuloma necrosis. We suggest that in PR
humans, those pathways may be initially intact but become
compromised over time due to non-genetic, environmental,
causes, creating phenocopies of mouse mutations. For exam-
ple, mice that carry the sst1 susceptible allele on the B6 back-
ground may recapitulate phenotypes associated with function-
al inactivation of the human homologue of Ipr1, SP110. The
inactivating mutations in Sp110 gene are present in human
populations at a very low frequency, because they cause se-
vere immune deficiency and susceptibility to opportunistic
infection Pneumocystis jirovecii and CMV [146]. However,
a number of studies found that the SP110 protein directly
interacts with viral proteins and is involved in control of mac-
rophage activation and death caused by chronic viral infec-
tions, such as EBV and hepatitis C virus [147, 148]. We hy-
pothesize that in human macrophages latently infected with
certain viruses, the expression of viral proteins may be upreg-
ulated within inflammatory lesions, such as granulomas.
Binding and sequestering SP110 by viral proteins would neu-
tralize its activity and create a phenocopy of the SP110 defi-
ciency in macrophages within granulomas, while systemic
immunity remains intact. This hypothetical scenario emerges
from the analysis of the Sp110 loss of function at the whole
organism level in mice and biochemical characterization of
viral protein interactors in isolated human cells in vitro. It
suggests a novel mechanism of the necrotic granuloma devel-
opment in immunocompetent humans, whereby viral co-
infections that primarily affect activated macrophages may
play a leading role. This example demonstrates that the genet-
ic dissection of TB in mouse models is capable of identifying
pathways and providing testable hypotheses relevant to TB
pathogenesis in real-life human populations.
To conclude, the fact that laboratory mice do not copy all
aspects of human disease does not invalidate the mouse mod-
el. On the contrary, if researchers stratify human phenotypes
and use genetically defined mouse models to match them, the
human and mouse studies demonstrate remarkable comple-
mentarity in the analysis of TB pathogenesis at the cellular
and whole organism levels.
Future directions
Because traditional mouse models and basic readouts were not
sufficiently aligned with other animal models and human TB,
they deemed unreliable for mechanistic and preclinical stud-
ies. These disputes during past decade have led to a situation
where tremendous progress in mouse genetics, genetic engi-
neering, and imaging has not been satisfactorily incorporated
into translational TB research. The situation started to change
with the broader acceptance of the C3HeB/FeJ model of ne-
crotic TB lesions for preclinical drug testing and in vivo im-
aging [62, 142]. However, as discussed above, no single
Bmouse TB^ model can reflect the mechanistically and mor-
phologically diverse forms of human TB. Therefore, the ques-
tion should not be Bwhether or which mouse is a good model
232 Semin Immunopathol (2016) 38:221–237
for human TB.^ Instead of comparing abstract Bhuman and
mouse TB,^ more relevant questions are how to best use the
existing and how to create new mouse models that resemble
specific forms of the human disease more accurately.
A particularly important application of the advancedmouse
models, uncontested by other methods, would be to study the
dynamics of human-like TB lesions in the lungs. In mice, as in
humans, advanced TB primarily targets and damages the lung.
Currently, the mechanistic basis of this key evolutionary trait
remains largely unknown. So far, most of the data on cell
interactions in granulomas was obtained using high-
resolution live imaging in zebrafish model and extrapolated
to human TB. These pioneering Bproof of principle^ imaging
and genetic studies now can be extended to study specific
contributions of the lung environment at different stages of
the granuloma progression and regression.
To date, many fundamental questions remain unanswered
with regard to pulmonary TB. For example, no experimental
data exist on the rate of macrophage survival in TB granulo-
mas. What is the time between a monocyte recruitment and
death in granulomas? Does the balance of cell death, clearance
of dead cells, and monocyte recruitment determine the appear-
ance and the dynamics of necrotic lesions? How the macro-
phage death modality affects the granuloma dynamics
in vivo? Howmuch replication of immune cells occurs locally
in granulomas? Do antigen-specific T cells directly interact
with infected phagocytes in different granuloma layers?
What is the outcome of these interactions? What are specific
roles of T lymphocytes in necrotization of TB granulomas?
Do T cells induce or prevent the necrotization? Does the neu-
trophil recruitment to granulomas precede or does it follow the
formation of micro-necrotic lesions? Ultimately, answering
these questions must reveal why effective systemic immunity
is not sufficient to control M.tb in lung granulomas and how
necrosis develops. Determining which factors can shift the
granuloma dynamics towards or away from the necrotic tra-
jectory is crucial for developing rational granuloma-directed
therapies to prevent or reverse the necrotization process. We
suggest that such anti-necrosis therapies may be directed at (i)
T cells—to activate or suppress specific subsets; (ii) macro-
phages—to increase macrophage longevity and resilience or
prime them for activation; and (iii) neutrophils—to block their
recruitment or enzymatic activities.
New quantitative criteria and tools for the analyses of TB
granuloma progression in mice have to be developed for in-
depth mechanistic analyses that also translate well into pre-
clinical studies. For example, using novel genetic and genetic
engineering tools, new generation mouse models can be cre-
ated that not only recapitulate a particular trait of the human
disease but also carry imaging and lineage tracking reporters
for its rapid quantitative analysis. In vivo and ex vivo imaging
techniques, such as MicroCT, PET, SPECT, and optical imag-
ing with an expanding array of functional imaging probes
provide a holistic view of pulmonary TB and allow quantita-
tive spatio-temporal assessment of individual TB lesions
based on inflammatory markers, myeloid cell recruitment,
and necrosis [144, 149]. Additionally, computer algorithms
are now being developed for automated detection of the cel-
lular composition in TB lung lesions at microscopic level
[150] and eventual quantification and reconstruction/model-
ing. Applying multi-modal imaging approaches will facilitate
functional analyses of host-pathogen interactions in situ—
within dynamic granulomas in lung-specific context.
Combination of the new generation mouse models with ad-
vanced imaging technologies will also allow rapid and inex-
pensive assessment of experimental vaccines and therapies
prior to testing in larger animals and clinical trials.
Bringing the new generation mouse models and readouts to
the field will also bolster the analyses of M.tb virulence and
pathogenesis in vivo. M.tbmutants and clinical isolates can be
systematically assessed for their ability to induce, and survive
within, lung necrotic granulomas. Mechanisms of M.tb reac-
tivation from latency and translocation from necrotic core out-
side granulomas, acquisition of drug tolerance, and evolution
of drug resistance, as well as drug distribution [143], all can be
studied in a context of mouse necrotic lung lesions in combi-
nation with bacterial reporters and advanced tools for induc-
ible gene expression and silencing.
In conclusion, the role that mouse models play in basic and
translational TB research will continue to increase allowing
researchers to address fundamental questions of TB pathogen-
esis and bacterial physiology in vivo with unparalleled depth.
This knowledge is not merely a pursuit of academicians but a
rational search to identify molecular targets that control necro-
sis, a key evolutionary determinant of M.tb propagation in
humans, to develop effective necrosis-directed therapies and
to test them in vivo with efficiency, mechanistic depth, and
quantitative rigor currently attainable only in a mouse model.
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